Anaeco Secures Strategic Investment from Momentum Global Ventures to Accelerate Commercial Deployment
5.10.2026 12:00:00 CEST | Business Wire | Press release
Investment supports commercialization across anesthetics, refrigerants, and semiconductor manufacturing
Anaeco, Inc., a clean technology company developing systems to destroy harmful and difficult-to-abate gases, today announced a strategic investment from Momentum Global Ventures. The investment supports Anaeco as it moves from technology development and validation to commercial deployment across three initial markets: anesthetic gases, refrigerants, and semiconductor manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005546122/en/
Anaeco’s technology exploits atmospheric chemistry to destroy harmful, high-impact gases, including HFCs, PFAS, anesthetic gases, N2O, and other difficult-to-abate emissions at their source. By accelerating processes that naturally transform pollutants, its modular technology provides a practical, scalable approach to emissions that are difficult or costly to manage conventionally.
Initial Commercial Verticals
Anesthetics: Destroying anesthetic gases generated in healthcare environments with a source-based approach.
Refrigerants: Destroying hydrofluorocarbons (HFCs) and other high-impact gases from HVAC, refrigeration, and refrigerant collection.
Semiconductor Manufacturing: Treating difficult-to-abate process emissions destruction as part of industrial manufacturing operations.
Anaeco has advanced its technology through real-world applications in the United States and Europe, including testing at a Danish hospital, collaboration with the City of Copenhagen, and are now participating in the Amazon Devices Climate Tech Accelerator. With its core technology developed and validated, Anaeco is focused on commercial deployment and expanding its customer base.
“We are thrilled to support the world-leading minds of the Anaeco team as they scale their U.S. and European activities from a transatlantic presence to a global platform. Our Anaeco investment focuses on breakthrough technologies that destroy some of the most harmful and difficult-to-abate emissions and prevent them from ending up in our bodies and the environment.”
— Joost Oostveen, Director, Momentum Global Ventures
“Anaeco grew from a simple scientific idea: The atmosphere already has effective chemistry for breaking down pollutants, so why not harness and accelerate it where harmful gases are emitted. That fundamental science has become a practical technology. This investment gives us the opportunity to take that science to a larger scale.”
— Matthew S. Johnson, Co-Inventor & Co-founder, Anaeco, Inc. and Professor of Chemistry, University of Copenhagen
“Turning university research into a company capable of real-world impact requires much more than a good scientific idea. It requires validation, persistence, strong partnerships and investment that can take the technology into the market. Anaeco’s progress illustrates that journey, and this investment represents an important next step in bringing a University of Copenhagen innovation to wider application.”
— Karin Beukel, Head of the Office, UCPH Lighthouse, University of Copenhagen
“This is a meaningful moment for deeptech, and it shows that a commercially compelling solution can deliver substantial climate impact. I am proud of what we’ve accomplished through years of perseverance and belief in our inventions.We are grateful and welcome Momentum Global Ventures as a partner in this next chapter.”
— Soheil Mansouri, Co-Inventor & Co-founder, Anaeco, Inc.
About Anaeco, Inc.
Anaeco, Inc. is a clean technology company developing systems that use accelerated atmospheric chemistry to destroy harmful and difficult-to-abate gases. Moving to commercial deployment and initially focused on anesthetic gases, refrigerants, and semiconductor manufacturing, Anaeco is headquartered in Nashville, Tennessee, with activities in the United States, Canada, and Europe. For more information, visit www.anaecosys.com.
About Momentum Global Ventures
Momentum Global Ventures is a global impact investor supporting technologies addressing significant challenges facing people and the planet, including climate technology, life sciences, clean water, artificial intelligence, and advanced technologies. For more information, visit www.momentum.ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261005546122/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 14:02:00 CEST | Press release
Special-Edition Korea-Made Skin Care Collection Launches In 40 Markets, Available While Supplies Last Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 14:00:00 CEST | Press release
Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1 GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subje
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 13:24:00 CEST | Press release
The installation marks a significant step in the evolution of premium No/Low wines, where preserving aroma and sensory quality has become a defining industry priority. Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking exper
Croma-Pharma Expands Its Portfolio in Canada With saypha® lips Lidocaine and Exprecell™5.10.2026 13:12:00 CEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform with the Addition of MOSS EOS for Early Onset Scoliosis Surgery5.10.2026 11:00:00 CEST | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the selective market introduction of the MOSS EOS® System for the treatment of children with severe early onset scoliosis.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005092768/en/ Early Onset Scoliosis is a rare pediatric disease where in certain cases surgical intervention can be indicated.2 Breaking new ground, Biedermann Motech will now introduce the world’s first MOSS EOS System featuring MOSS!MODULARITY™ to selective markets outside the U.S. The MOSS EOS System encompasses a modular platform of products and technologies for growth friendly pediatric spinal deformity surgery. Prof. Dr. Heiko Koller from Germany, one of the innovators behind the MOSS EOS System, carried out the first surgeries. His feedback was that the versatility of the system offers surgeons a broad range
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom